ArticleCancer medicine2024
Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeFew studies with a large sample size are available on patients with metabolic syndrome (MetS) receiving neoadjuvant treatment (NAT) for breast cancer. This study aimed to investigate the impact of MetS on the prognosis of patients with breast cancer undergoing NAT.
methodsThe data of patients with breast cancer receiving NAT at our center from January 2017 to December 2019 were retrospectively analyzed. A chi-square test and logistic regression model were applied to ascertain the factors associated with MetS and pathological complete response (pCR). The Cox proportional risk model was employed for univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS).
resultsOf the 910 patients enrolled, 164 (18.0%) were diagnosed with MetS, 568 (62.4%) with stage II, and 342 (37.6%) with stage III. Postmenopausal status (p = 0.045) and stage III (p = 0.009) were associated with a higher incidence rate of MetS. MetS was associated with a lower pCR rate (p = 0.027). The 5-year DFS (83.7% vs. 73.1%, p = 0.001) and OS (92.8% vs. 85.5%, p = 0.001) of the non-MetS group were significantly better than those of the MetS group. In premenopausal women, the DFS (p = 0.001) and OS (p = 0.025) of the non-MetS group were significantly better than those of the MetS group. No significant differences were noted in DFS (p = 0.270) or OS (p = 0.078) between the two groups in postmenopausal women. In the Cox proportional risk model, MetS acted as an independent factor associated with DFS (HR = 1.705, 95% CI: 1.201-2.421, p = 0.003) and OS (HR = 1.874, 95% CI: 1.149-3.055, p = 0.012).
conclusionMetS was associated with poor prognosis in patients with breast cancer receiving NAT. Hence, close attention should be paid to patients with breast cancer who have MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.